Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1315 - Natural history and prognostic factors of head and neck cancer patients with bone metastases: a retrospective Italian study

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Head and Neck Cancers

Presenters

Salvatore Grisanti

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

S. Grisanti1, C. Bergamini2, S. Bianchi1, A. Baiguini3, S. Vecchio4, L.D. Locati2, A. Bonetta5, P.F. Conte6, M. Airoldi7, M. Merlano8, P. Carlini9, T. Ibrahim10, C. Rossetto11, P. Nicolai12, R. Maroldi13, S. Tonoli5, P. Pronzato4, S.M. Magrini3, L. Licitra2, A. Berruti1

Author affiliations

  • 1 Medical Oncology, Azienda Ospedaliera Spedali Civili di Brescia and University of Brescia, 25123 - Brescia/IT
  • 2 Medical Oncology Unit/head And Neck Unit, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan/IT
  • 3 Radiation Oncology, Azienda Ospedaliera Spedali Civili di Brescia and University of Brescia, 25123 - Brescia/IT
  • 4 Medical Oncology, IRCCS San Martino, IST National Cancer Institute and University of Genova, Genova/IT
  • 5 Radiation Oncology, Cremona Hospital, Cremona/IT
  • 6 Department Of Surgery, Oncology And Gastroenterology, University of Padova and Istituto Oncologico Veneto IRCCS, 35100 - Padova/IT
  • 7 Medical Oncology, AOU S. Giovanni Battista - Molinette, 10126 - Torino/IT
  • 8 Oncology Department, S. Croce & Carle Teaching Hospital, 12100 - Cuneo/IT
  • 9 Medical Oncology, Regina Elena National Cancer Institute, Rome/IT
  • 10 Osteoncology And Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola/IT
  • 11 Oncology, University Hospital Santa Maria della Misericordia, Udine/IT
  • 12 Otorhinolaryngology Unit, Azienda Ospedaliera Spedali Civili di Brescia and University of Brescia, 25123 - Brescia/IT
  • 13 Radiology Unit, Azienda Ospedaliera Spedali Civili di Brescia and University of Brescia, 25123 - Brescia/IT
More

Resources

Abstract 1315

Background

We performed a retrospective survey to study the natural history and the prognostic factors of patients (pts) with bone metastases (BMs) from head and neck cancers (HNCs).

Methods

Clinical records of pts treated at 11 oncologic centers across Italy were retrieved. All pts were selected on the base of BMs either at diagnosis or at subsequent time points. Pts with a diagnosis of nasopharyngeal carcinoma (NPC) were analyzed separately. The time-to-first bone metastasis was calculated from initial diagnosis. The skeletal-related events (SREs) (fractures, medullary compression, hypercalcemia) were recorded from the date of BMs diagnosis.

Results

From 2008 to 2016, 192 HNC pts with BMs (64 NPCs and 128 other-HNCs) were collected. Median time to first BM was 9 and 12 months for NPCs and other-HNCs, respectively. SREs occurred in 9% and 27% NPC and other-HNC pts, respectively. Pts received specific antineoplastic treatments (92%) or best supportive care (8%). Median progression free survival (PFS) and overall survival (OS) were 11 and 25 months in NPC-BM pts and only 5 and 6 months in other-HNC-BM pts, respectively. SRE did not affect the pt prognosis except for hypercalcemia that was associated with a poorer prognosis (not significant). Biphosphonates and/or denosumab were administered in 34% NPC and 33% other-HNC pts, respectively. The administration of bone-directed therapies, also including radiation therapy and surgery on BMs, was associated with a better survival at univariate analysis in both NPC and other-HNC (Hazard Ratio [HR]: 0.43, 95% confidence interval [CI] .008-.237, p

Conclusions

In HNC pts destined to develop BMs, these events occur early in the natural history of these diseases. The onset of BMs predicts a poor survival in non-NPC HNC pts. SREs are more frequent in non-NPC HNC pts. Bone directed therapies are correlated with better outcome.

Clinical trial identification

Id NP1848 - Study SURMOS - Release date: 11 Dec 2014

Legal entity responsible for the study

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili Hospital, Medical Oncology Unit, Brescia, Italy

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.